JP2018537514A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537514A5
JP2018537514A5 JP2018531667A JP2018531667A JP2018537514A5 JP 2018537514 A5 JP2018537514 A5 JP 2018537514A5 JP 2018531667 A JP2018531667 A JP 2018531667A JP 2018531667 A JP2018531667 A JP 2018531667A JP 2018537514 A5 JP2018537514 A5 JP 2018537514A5
Authority
JP
Japan
Prior art keywords
composition
bladder
use according
hal
light
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018531667A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537514A (ja
JP6926086B2 (ja
Filing date
Publication date
Priority claimed from GBGB1522309.2A external-priority patent/GB201522309D0/en
Application filed filed Critical
Publication of JP2018537514A publication Critical patent/JP2018537514A/ja
Publication of JP2018537514A5 publication Critical patent/JP2018537514A5/ja
Application granted granted Critical
Publication of JP6926086B2 publication Critical patent/JP6926086B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018531667A 2015-12-17 2016-12-19 膀胱癌のための術前補助療法 Active JP6926086B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1522309.2A GB201522309D0 (en) 2015-12-17 2015-12-17 Use
GB1522309.2 2015-12-17
PCT/EP2016/081803 WO2017103283A1 (en) 2015-12-17 2016-12-19 Neoadjuvant therapy for bladder cancer

Publications (3)

Publication Number Publication Date
JP2018537514A JP2018537514A (ja) 2018-12-20
JP2018537514A5 true JP2018537514A5 (https=) 2020-02-06
JP6926086B2 JP6926086B2 (ja) 2021-08-25

Family

ID=55311159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018531667A Active JP6926086B2 (ja) 2015-12-17 2016-12-19 膀胱癌のための術前補助療法

Country Status (13)

Country Link
US (2) US10556010B2 (https=)
EP (1) EP3389717B9 (https=)
JP (1) JP6926086B2 (https=)
KR (1) KR102787188B1 (https=)
CN (2) CN119345359A (https=)
AU (1) AU2016372573B2 (https=)
BR (1) BR112018012009B1 (https=)
DK (1) DK3389717T3 (https=)
ES (1) ES3015668T3 (https=)
FI (1) FI3389717T3 (https=)
GB (1) GB201522309D0 (https=)
PL (1) PL3389717T3 (https=)
WO (1) WO2017103283A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522311D0 (en) 2015-12-17 2016-02-03 Photocure Asa Use
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
MY181242A (en) 2017-12-01 2020-12-21 Sbi Pharmaceuticals Co Ltd Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor
KR102441358B1 (ko) 2020-09-14 2022-09-06 주식회사 아파트엔 아파트의 지수화를 통한 아파트 투자 가치 평가 시스템
KR20250154511A (ko) 2023-03-07 2025-10-28 포토큐어 에이에스에이 방광암 치료
WO2026052815A1 (en) 2024-09-05 2026-03-12 Photocure Asa Use of hal in a method for predicting bladder cancer immunotherapy response

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7530461B2 (en) * 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
HU225148B1 (en) 1995-03-10 2006-07-28 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy or diagnosis, products and kits comprising thereof and method of in vitro diagnosis by their using
GB0018528D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Compounds
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
SI2440199T1 (sl) 2009-06-11 2016-05-31 Photocure Asa Poltrdni sestavki in farmacevtski proizvodi
MX368257B (es) 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-pd-l1 항체 및 그의 용도
RU2689760C2 (ru) 2012-05-31 2019-05-30 Дженентек, Инк. Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
US8927761B2 (en) 2012-06-28 2015-01-06 Photocure Asa Form of hexyl-5-aminolevulinate hydrochloride and methods of using the same
ES2908080T3 (es) * 2012-08-03 2022-04-27 Photocure Asa Compuestos
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
CN109010850B (zh) * 2018-08-01 2021-10-22 上海师范大学 一种负载姜黄素的葡聚糖修饰的钆掺杂的空心介孔二氧化硅纳米材料的制备方法及应用

Similar Documents

Publication Publication Date Title
JP2018537514A5 (https=)
JP2014094963A5 (https=)
RU2013121788A (ru) Ингибиторы репликации вич
NZ609719A (en) Pharmaceutical composition
AR074826A1 (es) Regimen de dosificacion para un agonista de los receptores de s1p
MX360684B (es) Silicato de zirconio microporoso para el tratamiento de la hipercalemia.
RU2012118974A (ru) Комбинации ингибитора pi3k и ингибитора мек
JP2015511609A5 (https=)
JP2020507589A5 (https=)
FI3389717T3 (fi) Neoadjuvanttihoito virtsarakon syöpää varten
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
JP2016501066A5 (https=)
JP2018538308A5 (https=)
JP2019501161A5 (https=)
RU2008105590A (ru) ПРИМЕНЕНИЕ 3, 11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИНА ДЛЯ ЛЕЧЕНИЯ СИМПТОМОВ БОЛЕЗНИ ГЕНТИНГТОНА
JP2016527202A5 (https=)
JP2017513927A5 (https=)
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
RU2018123834A (ru) Способ фотодинамической терапии (фдт) для рака мочевого пузыря
RU2007118691A (ru) Применение 4-трифторметилфениламида (z)-2-циано-3-гидрокси-бут-2-еновой кислоты для лечения воспалительных заболеваний кишечника
JP2015512923A5 (https=)
MX2022009081A (es) Absorcion celular.
RU2012122649A (ru) Способ диагностики ишемии миокарда у больных кардиальным синдромом х
CO6270205A2 (es) Formulacion que contiene un compuesto inhibidor de quinasa dependiente de ciclina y metodo para tratar tumores utilizando el mismo